Concepedia

Keith Morrison

KM

10

Publications

831

Citations

10

H-Index

2004

Active since

Affiliations

Actelion (Switzerland)(Current)

Idorsia (Switzerland)

Keith Morrison is an author at Actelion (Switzerland) specializing in drug discovery, medicinal chemistry, and clinical pharmacology.

ORCID

Top concepts

Publications per year

2004–2023

10

Publications

10

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

Marc Iglarz, Christoph A. Binkert, Keith Morrison et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 320 citations

Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System

Martine Clozel, Christoph A. Binkert, Magdalena Birker et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 132 citations · Full text

Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension

Tetsuo Asaki, Keiichi Kuwano, Keith Morrison et al. · Journal of Medicinal Chemistry · 2015 · 86 citations

, , +21

Novel Benzo[1,4]diazepin-2-one Derivatives as Endothelin Receptor Antagonists

Martin H. Bolli, Judith Marfurt, Corinna Grisostomi et al. · Journal of Medicinal Chemistry · 2004 · 76 citations · Full text

Selexipag: A Selective Prostacyclin Receptor Agonist that Does Not Affect Rat Gastric Function

Keith Morrison, Roland Ernst, Patrick Hess et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 63 citations

Rows per page

1–5 of 10